Exane Derivatives Neogenomics Inc Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Neogenomics Inc stock. As of the latest transaction made, Exane Derivatives holds 151 shares of NEO stock, worth $2,594. This represents 0.0% of its overall portfolio holdings.
Number of Shares
151
Previous 2,227
93.22%
Holding current value
$2,594
Previous $27,000
96.3%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding NEO
# of Institutions
295Shares Held
125MCall Options Held
698KPut Options Held
120K-
Black Rock Inc. New York, NY19.7MShares$338 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14MShares$241 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$118 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$113 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$112 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $2.16B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...